AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00801151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolinza (vorinostat), vinorelbine
Description: Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication.
Study NCT01305837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg of methylprednisolone taken in 3 days every month
Study NCT02185586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Study NCT02185586 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic cholecystectomy
Study NCT01699178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
Study NCT01699178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone gel (AndroGel)
Description: Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
Study NCT01261793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study NCT01261793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study NCT01261793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
Study NCT01261793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Study NCT04887597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The study is composed of a single arm receiving secukinumab for the duration of 6 months.
Study NCT00293085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00293085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines.
Study NCT03031223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: low-level laser therapy
Study NCT03031223 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: low-level laser therapy
Description: low-level laser therapy
Study NCT03522844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
Study NCT03522844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
Study NCT01537263 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Perfusion Imaging
Description: Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
Study NCT01658176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
Study NCT01658176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane administered orally at 25 mg as a continuous daily dosing schedule
Study NCT01658176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane administered orally at 25 mg as a continuous daily dosing schedule
Study NCT04031534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-Miso PET scan coupled with MRI
Description: Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
Study NCT03988855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNV3837
Description: Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
Study NCT02848898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi
Study NCT02848898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00593983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
Study NCT00593983 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-matched health education
Description: Health education and standard of care treatment
Study NCT02241980 — intervention group
Intervention type: OTHER
Intervention: Patient survey
Study NCT02241980 — intervention group
Intervention type: OTHER
Intervention: Physician survey
Study NCT00336375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.
Study NCT00336375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.
Study NCT04320472 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
Study NCT03473652 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adapted walking platform
Description: The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
Study NCT03562117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
Study NCT01796834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
Study NCT02954276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omexa Sublingual Sumatriptan tablet
Description: 75 mg
Study NCT02954276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex Oral Product
Description: 100 mg
Study NCT03867123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
Study NCT03867123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
Study NCT03867123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
Study NCT01911819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus augmentation
Study NCT00816244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
Study NCT01399619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 24 or 48w
Study NCT01399619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: BI201335 for 12w
Study NCT01399619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335 24W
Description: BI201335 for 24w
Study NCT01399619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bi 201335
Description: BI 201335 for 24 w
Study NCT02384590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy
Description: The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience.
Study NCT04373265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant, 100 mg soft gel capsules orally once daily
Study NCT04373265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg infusion every 6 weeks
Study NCT02497261 — intervention group
Intervention type: PROCEDURE
Intervention: Double-blind placebo-controlled peanut challenge
Description: Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
Study NCT03917966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+docetaxel+nedaplatin
Description: neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
Study NCT03917966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+Apatinib
Description: SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
Study NCT01043809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procter & Gamble school-based handwashing promotion program
Description: Handwashing promotion lesson and materials targeting first grade students
Study NCT01043809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expanded school-based handwashing promotion
Description: Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
Study NCT03271580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Finger prick test for HbA1c measurement
Description: HbA1c measurement with finger prick method
Study NCT03271580 — intervention group
Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
Study NCT03271580 — intervention group
Intervention type: OTHER
Intervention: Vac Sponge Collection
Description: NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
Study NCT00838526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole ER
Description: 50 mg capsule, taken orally, once daily for 26 weeks.
Study NCT00838526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Study NCT00578201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiochemotherapy,combination Cetuximab-FOLFOX
Description: objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
Study NCT01522456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo Gel
Description: Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
Study NCT01076530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02795585 — intervention group
Intervention type: OTHER
Intervention: QFR (observational)
Description: QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
Study NCT00529425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT00529425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Study NCT01652339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge tab. 10/160mg
Study NCT01652339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivixx tab. 5/160mg
Study NCT00038064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
Study NCT00038064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 150 IU/kg TIW
Study NCT01911819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equimatrix
Description: Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
Study NCT01911819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSSIF-i sem
Description: OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
Study NCT01911819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-oss
Description: Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
Study NCT00246350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 8 light massage treatments and hot pack
Study NCT01522456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A Micro Microsphere 0.1%
Description: Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
Study NCT01467297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftidoren
Description: ceftidoren 200 mg bid for 5 days
Study NCT01467297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: levofloxacin 500 mg once daily for 7 days
Study NCT01400542 — intervention group
Intervention type: DEVICE
Intervention: CPAP Treatment
Description: Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
Study NCT01400542 — intervention group
Intervention type: DEVICE
Intervention: No treatment
Description: no treatment
Study NCT02329028 — intervention group
Intervention type: DEVICE
Intervention: Prehospital mini-EEG
Description: Observational
Study NCT04478929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy
Description: Routine gastroscopy
Study NCT00246350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 16 light massage treatments and hot packs
Study NCT01509339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study NCT03805386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician directed opioid prescribing
Description: Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
Study NCT03805386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient directed opioid prescribing
Description: Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
Study NCT00246350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: 8 high velocity, low amplitude spinal manipulation treatments and hot pack
Study NCT00246350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: 16 high velocity, low amplitude spinal manipulation treatments and hot pack
Study NCT02902224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: 300ml tap water via nasogastric tube
Study NCT02902224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g glucose via nasogastric tube
Study NCT02902224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 300ml tap water with 25g fructose via nasogastric tube
Study NCT02658253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRIMVAC
Description: 3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
Study NCT03271580 — intervention group
Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Blood pressure test
Study NCT05791123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket
Description: Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
Study NCT00740129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg intravenous infusion once
Study NCT04298307 — intervention group
Intervention type: OTHER
Intervention: Intracoronary lithotripsy (ICL)
Description: ICL using the Shockwave catheter.
Study NCT02303327 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: EBRT + HDR brachytherapy boost
Description: Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
Study NCT02303327 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Dose Escalation Radiotherapy
Description: Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
Study NCT02303327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Androgen deprivation therapy
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Study NCT02303327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: 28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Study NCT02620566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain- Caudal
Description: Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
Study NCT02620566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- Local
Description: Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
Study NCT00256724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance Threshold Device
Description: Active impedance threshold device
Study NCT00256724 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ITD
Description: sham impedance threshold device